Abstract
Erdafitinib (Balversa™, Janssen Pharmaceutical Companies) is a pan-fibroblast growth factor receptor (FGFR) inhibitor that was recently approved in the USA for the treatment of locally advanced or metastatic FGFR3 or FGFR2 urothelial carcinoma. The drug is also being investigated as a treatment for other cancers including cholangiocarcinoma, liver cancer, non-small cell lung cancer, prostate cancer, lymphoma and oesophageal cancer. This article summarizes the milestones in the development of erdafitinib leading to this first approval for the treatment of urothelial carcinoma.
MeSH terms
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Carcinoma, Transitional Cell / drug therapy*
-
Carcinoma, Transitional Cell / pathology
-
Drug Approval
-
Humans
-
Protein Kinase Inhibitors / pharmacology
-
Protein Kinase Inhibitors / therapeutic use*
-
Pyrazoles / therapeutic use*
-
Quinoxalines / therapeutic use*
-
Receptor, Fibroblast Growth Factor, Type 2 / antagonists & inhibitors
-
Receptor, Fibroblast Growth Factor, Type 2 / metabolism
-
Receptor, Fibroblast Growth Factor, Type 3 / antagonists & inhibitors
-
Receptor, Fibroblast Growth Factor, Type 3 / metabolism
-
Treatment Outcome
-
United States
-
United States Food and Drug Administration / legislation & jurisprudence
-
Urologic Neoplasms / drug therapy*
-
Urologic Neoplasms / pathology
Substances
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
Pyrazoles
-
Quinoxalines
-
erdafitinib
-
FGFR2 protein, human
-
FGFR3 protein, human
-
Receptor, Fibroblast Growth Factor, Type 2
-
Receptor, Fibroblast Growth Factor, Type 3